R&D is the heart of fulfilling Novugen's purpose and our main drive towards innovation. Located in the heart of Southeast Asia, our global R&D centre is based in Malaysia with highly experienced scientists. We focus on difficult to develop, technology-intensive products including complex generics conforming to USFDA standards.
We have full capabilities to handle development services for a variety of dosage forms including:
Tablets, capsules and powders
Pellets and beads
Liquids, solutions, suspensions and emulsions
Soft Gel capsules
Parental Dosage Forms (Liquid and Lyophilized powders)
Granules for reconstitution
Drug in capsule/vial for clinical trials
Other Novel dosage forms(e.g MUPS, OCAS, DDR , etc.)
Novugen invests and re-invests in advanced technologies and highly experienced scientists to target difficult to develop and technology intensive products. Our advanced analytical lab and high-containment research centre in Malaysia for oncology and other therapeutic areas, support solid state characterisation for API & Finished Products to establish sameness with the brand product. This enables us to pass all bioequivalence studies from EU and USFDA approved Clinical Research Organizations (CRO’s).
